World Cancer-Treating Drugs Market Set To Grow To $152bn By 2022

10 August 2018
Pharma

Visiongain has launched a new pharma report World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs

The future of the anti-cancer drugs market looks promising, as a number of new and innovative therapies are coming on to the market. In recent years there has been a remarkable improvement in the safety of products, with improvements of delivery of chemotherapy, among other techniques, reducing the toxicity of treatments.

The lead analyst of the report commented “’The anti-cancer treatments market will see strong growth driven by the ageing population, increasing demand of biological and targeted drug therapies, continuous patent expiry of major cancer drugs with generic competition eroding their share of the market and the rising uptake of biosimilars.

The anti-cancer drugs pipeline includes monoclonal antibodies, new classes of novel antineoplastics (including PARP inhibitors) and therapeutic vaccines. The launch of emerging classes, including immuno-oncologics, and combination therapies will offer potential breakthrough in cancer treatment. On a global context, the US will remain the largest market while emerging markets will see the highest rate of growth”

Leading companies featured in the report include AstraZeneca, Merck & Co., Inc. (Merck), Novartis, Amgen, Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Roche, Eli Lilly and Celgene.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever